Sensus Healthcare reportedly postponed its initial public offering today, after setting terms earlier this month with a midpoint raise of $20 million.
Boca Raton, Fla.-based Sensus makes the SRT-100 and SRT-100 Vision photon X-ray low-energy superficial radiotherapy systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas. The company said March 9 that it planned to float more than 1.8 million shares at $10 to $12 apiece, working out to a low-end raise of $18.2 million and a high end of $21.8 million.
A mere 8 IPOs have priced in 2016, all in the healthcare sector, according to Renaissance Capital, which 1st reported the Sensus tabling.
The SRT-100 system has U.S. 510(k) clearance, CE Mark approval in the European Union and approvals from the China Food & Drug Administration and Health Canada; Sensus claims more than 200 installed devices in 11 countries.
The company had planned to put $3 million of the IPO proceeds toward hiring new sales reps and a director of marketing, and another $3 million into R&D for new products and the further development of existing products. Some $2.7 million was to have gone toward paying a dividend to a former shareholders who elect not to convert their dividends into shares after the IPO, Sensus said at the time.
The post Sensus Healthcare postpones IPO appeared first on MassDevice.
from MassDevice http://ift.tt/1TiKpIA
Cap comentari:
Publica un comentari a l'entrada